Search research articles
Contact Us
Filters
Showing results (241-250 of 288) with videos related to
Page
of 29
Sort By:
Journal of Hematology & Oncology
|
January 7, 2014
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
L Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, et al.
Cancer Chemotherapy and Pharmacology
|
September 17, 2008
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
Chia-Chi Lin, Emiliano Calvo, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology
|
March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
Amita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2022
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i><sup></sup> Solid Tumors (KRYSTAL-1)
Sai-Hong Ignatius Ou, Pasi A Jänne, Ticiana A Leal, et al.
British Journal of Haematology
|
April 14, 2016
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
Susan J Lee, Konstantin Levitsky, Francesco Parlati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2010
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas
Monica M Mita, Matthew A Spear, Lorrin K Yee, et al.
The Oncologist
|
May 4, 2021
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Hani Babiker, Irene Brana, Daruka Mahadevan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2026
Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors
Kyriakos P Papadopoulos, Manish R Sharma, Reinhard Dummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2018
SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads
Krista Kinneer, John Meekin, Arnaud C Tiberghien, et al.
British Journal of Cancer
|
November 14, 2018
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz Dit Busset, et al.
Page
of 29
Search research articles
Search
Showing results (241-250 of 288) with videos related to
Sort By:
Page
of 29
Journal of Hematology & Oncology
|
January 7, 2014
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
L Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, et al.
Cancer Chemotherapy and Pharmacology
|
September 17, 2008
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
Chia-Chi Lin, Emiliano Calvo, Kyriakos P Papadopoulos, et al.
Cancer Chemotherapy and Pharmacology
|
March 18, 2014
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors
Amita Patnaik, Patricia M LoRusso, Wells A Messersmith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2022
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced <i>KRAS</i><sup></sup> Solid Tumors (KRYSTAL-1)
Sai-Hong Ignatius Ou, Pasi A Jänne, Ticiana A Leal, et al.
British Journal of Haematology
|
April 14, 2016
Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
Susan J Lee, Konstantin Levitsky, Francesco Parlati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2010
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas
Monica M Mita, Matthew A Spear, Lorrin K Yee, et al.
The Oncologist
|
May 4, 2021
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Hani Babiker, Irene Brana, Daruka Mahadevan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 22, 2026
Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors
Kyriakos P Papadopoulos, Manish R Sharma, Reinhard Dummer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 23, 2018
SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads
Krista Kinneer, John Meekin, Arnaud C Tiberghien, et al.
British Journal of Cancer
|
November 14, 2018
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro, Bassel F El-Rayes, Michele Droz Dit Busset, et al.
Page
of 29